PT1766012E - Método e composto antisense antibacteriano - Google Patents
Método e composto antisense antibacteriano Download PDFInfo
- Publication number
- PT1766012E PT1766012E PT05857499T PT05857499T PT1766012E PT 1766012 E PT1766012 E PT 1766012E PT 05857499 T PT05857499 T PT 05857499T PT 05857499 T PT05857499 T PT 05857499T PT 1766012 E PT1766012 E PT 1766012E
- Authority
- PT
- Portugal
- Prior art keywords
- bases
- compound
- bacterial
- antisense compounds
- mrna
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000000692 anti-sense effect Effects 0.000 title abstract 4
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 108010077805 Bacterial Proteins Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108091081024 Start codon Proteins 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65613—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. cephalosporins and analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58511204P | 2004-07-02 | 2004-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1766012E true PT1766012E (pt) | 2011-09-05 |
Family
ID=36686070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05857499T PT1766012E (pt) | 2004-07-02 | 2005-07-01 | Método e composto antisense antibacteriano |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8314072B2 (pt) |
| EP (2) | EP1766012B1 (pt) |
| AT (1) | ATE510914T1 (pt) |
| AU (1) | AU2005327188C9 (pt) |
| CA (2) | CA2571593C (pt) |
| CY (1) | CY1111765T1 (pt) |
| DK (1) | DK1766012T3 (pt) |
| ES (1) | ES2367289T3 (pt) |
| PL (1) | PL1766012T3 (pt) |
| PT (1) | PT1766012E (pt) |
| SI (1) | SI1766012T1 (pt) |
| WO (1) | WO2006085973A2 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| ATE510914T1 (de) | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| CA2614191C (en) * | 2005-07-13 | 2015-06-30 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| ES2386578T3 (es) * | 2006-05-05 | 2012-08-23 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de PCSK9 |
| HUE036995T2 (hu) * | 2006-05-10 | 2018-08-28 | Sarepta Therapeutics Inc | Az alegységek között kationos kötéssel rendelkezõ oligonukleotid analógok |
| TW200838551A (en) * | 2006-11-27 | 2008-10-01 | Isis Pharmaceuticals Inc | Methods for treating hypercholesterolemia |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| PL2585596T3 (pl) * | 2010-06-23 | 2021-06-28 | Curna, Inc. | Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| EP3067420A1 (en) * | 2010-11-12 | 2016-09-14 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
| US9078911B2 (en) | 2011-02-08 | 2015-07-14 | The Charlotte-Mecklenburg Hospital Authority | Antisense oligonucleotides |
| JP2015500204A (ja) | 2011-11-18 | 2015-01-05 | サレプタ セラピューティクス， インコーポレイテッド | 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット |
| EP2828395B1 (en) | 2012-03-20 | 2018-10-24 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| JP6901966B2 (ja) | 2014-05-16 | 2021-07-14 | オレゴン ステート ユニバーシティ | アンチセンス抗菌化合物および方法 |
| US10391098B2 (en) | 2014-05-19 | 2019-08-27 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US10266823B2 (en) * | 2014-07-01 | 2019-04-23 | The University Of North Carolina At Chapel Hill | Small molecules that enhance the activity of oligonucleotides |
| AU2015372560B2 (en) | 2014-12-31 | 2021-12-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| US10907158B2 (en) | 2015-12-23 | 2021-02-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217866A (en) * | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) * | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| WO1986005519A1 (en) * | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| JP3398378B2 (ja) | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
| US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| KR970005274B1 (ko) | 1990-08-14 | 1997-04-15 | 아이시스 파마슈티칼스, 인코포레이티드 | 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보스트레인(ann arbor strain) h2n2의 억제 |
| WO1993001286A2 (en) | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US5821052A (en) | 1992-04-16 | 1998-10-13 | University Of Medicine And Dentistry Of New Jersey | Control of the synthesis of proteins by anitisense RNA-tRNA complex |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| US6060456A (en) * | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5479847A (en) * | 1994-11-07 | 1996-01-02 | Marlen Research Corporation | Dual-piston pump apparatus |
| GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| GB9510718D0 (en) * | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| EP0966303A2 (en) | 1996-05-01 | 1999-12-29 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| AU3811897A (en) | 1996-07-24 | 1998-02-10 | Oglios Therapeutics, Inc. | Antisense oligonucleotides as antibacterial agents |
| ATE291617T1 (de) | 1997-01-24 | 2005-04-15 | Avi Biopharm Inc | Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen |
| CN1263473A (zh) * | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
| US6204019B1 (en) | 1997-06-04 | 2001-03-20 | Smithkline Beecham Corporation | Sec A2 from Streptococcus pneumoniae |
| US6610539B1 (en) | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
| EP0894857A3 (en) | 1997-08-01 | 2001-09-26 | Smithkline Beecham Corporation | SecA gene from Streptococcus pneumoniae |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6228579B1 (en) * | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
| US6548651B1 (en) * | 1998-11-11 | 2003-04-15 | Pantheco A/S | Modified peptide nucleic acid (PNA) molecules |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| EP1173561A2 (en) * | 1999-01-29 | 2002-01-23 | Avi Biopharma, Inc. | Non-invasive method for detecting target rna |
| US6521438B1 (en) * | 1999-11-05 | 2003-02-18 | North Carolina State University | Chemoreceptors in plant parasitic nematodes |
| US20030095953A1 (en) * | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
| EP1238071B1 (en) * | 1999-11-29 | 2008-04-23 | Avi Biopharma, Inc. | Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses |
| KR20020079768A (ko) * | 2000-01-04 | 2002-10-19 | 에이브이아이 바이오파마 인코포레이티드 | 안티센스 항박테리아 세포분열 조성물 및 방법 |
| US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| US20040072743A1 (en) * | 2000-04-06 | 2004-04-15 | Christensen Jeppe Viggo | Pharmaceutical composition of modified pna molecules |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| EP1301525B1 (en) * | 2000-07-06 | 2015-09-02 | Sarepta Therapeutics, Inc. | Transforming growth factor beta (tgf-beta) blocking agent-treated stem cell composition and method |
| MXPA03003690A (es) * | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
| WO2002079467A2 (en) * | 2001-03-29 | 2002-10-10 | Københavns Universitet | Antibiotic-free bacterial strain selection with antisense molecules |
| US20030125241A1 (en) * | 2001-05-18 | 2003-07-03 | Margit Wissenbach | Therapeutic uses of LNA-modified oligonucleotides in infectious diseases |
| US6828105B2 (en) * | 2001-10-16 | 2004-12-07 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20030224353A1 (en) * | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| AU2003280247A1 (en) * | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| ES2351976T3 (es) | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
| KR20060015612A (ko) * | 2003-05-23 | 2006-02-17 | 으뻬에프엘-에꼴 뽈리떼끄니끄 페데랄르 드 로잔느 | 아실 캐리어 단백질을 기본으로 한 단백질 라벨링 방법 |
| AU2004276226B2 (en) | 2003-08-05 | 2009-07-30 | Avi Biopharma, Inc. | Oligonucleotide analog and method for treating flavivirus infections |
| US7402574B2 (en) | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| ATE510914T1 (de) | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| CA2614191C (en) | 2005-07-13 | 2015-06-30 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| HUE036995T2 (hu) | 2006-05-10 | 2018-08-28 | Sarepta Therapeutics Inc | Az alegységek között kationos kötéssel rendelkezõ oligonukleotid analógok |
| EP2732035A2 (en) | 2011-07-15 | 2014-05-21 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
-
2005
- 2005-07-01 AT AT05857499T patent/ATE510914T1/de active
- 2005-07-01 CA CA 2571593 patent/CA2571593C/en not_active Expired - Fee Related
- 2005-07-01 DK DK05857499.7T patent/DK1766012T3/da active
- 2005-07-01 PT PT05857499T patent/PT1766012E/pt unknown
- 2005-07-01 WO PCT/US2005/023553 patent/WO2006085973A2/en active Application Filing
- 2005-07-01 SI SI200531354T patent/SI1766012T1/sl unknown
- 2005-07-01 EP EP05857499A patent/EP1766012B1/en not_active Expired - Lifetime
- 2005-07-01 PL PL05857499T patent/PL1766012T3/pl unknown
- 2005-07-01 US US11/173,847 patent/US8314072B2/en not_active Expired - Fee Related
- 2005-07-01 AU AU2005327188A patent/AU2005327188C9/en not_active Ceased
- 2005-07-01 CA CA2875436A patent/CA2875436A1/en not_active Abandoned
- 2005-07-01 ES ES05857499T patent/ES2367289T3/es not_active Expired - Lifetime
- 2005-07-01 EP EP10013182A patent/EP2351839A3/en not_active Withdrawn
-
2006
- 2006-05-10 US US11/432,216 patent/US7625873B2/en not_active Expired - Fee Related
-
2009
- 2009-11-05 US US12/613,428 patent/US20100137408A1/en not_active Abandoned
-
2011
- 2011-08-18 CY CY20111100790T patent/CY1111765T1/el unknown
-
2012
- 2012-11-19 US US13/680,790 patent/US9534220B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CY1111765T1 (el) | 2015-10-07 |
| PL1766012T3 (pl) | 2011-11-30 |
| AU2005327188C1 (en) | 2011-07-07 |
| ES2367289T3 (es) | 2011-11-02 |
| EP1766012A2 (en) | 2007-03-28 |
| AU2005327188B2 (en) | 2011-03-17 |
| EP2351839A2 (en) | 2011-08-03 |
| WO2006085973A2 (en) | 2006-08-17 |
| AU2005327188C8 (en) | 2011-09-22 |
| WO2006085973A3 (en) | 2007-04-12 |
| EP1766012B1 (en) | 2011-05-25 |
| EP2351839A3 (en) | 2011-10-05 |
| US20130289091A1 (en) | 2013-10-31 |
| ATE510914T1 (de) | 2011-06-15 |
| AU2005327188C9 (en) | 2011-09-22 |
| CA2571593A1 (en) | 2006-08-17 |
| US20070021362A1 (en) | 2007-01-25 |
| SI1766012T1 (sl) | 2011-10-28 |
| US9534220B2 (en) | 2017-01-03 |
| CA2875436A1 (en) | 2006-08-17 |
| AU2005327188A1 (en) | 2006-08-17 |
| DK1766012T3 (da) | 2011-09-19 |
| US20070049542A1 (en) | 2007-03-01 |
| US20100137408A1 (en) | 2010-06-03 |
| US7625873B2 (en) | 2009-12-01 |
| US8314072B2 (en) | 2012-11-20 |
| CA2571593C (en) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111765T1 (el) | Αντινοηματικη αντιβακτηριακη μεθοδος και ενωση | |
| WO2007009094A3 (en) | Antisense antibacterial method and compound | |
| DE69934242D1 (de) | Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen | |
| WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
| WO2007056326A3 (en) | Compositions and methods for inhibiting expression of nav1.8 gene | |
| MX2007002382A (es) | Producci??n de anticuerpos anti-amiloides beta. | |
| WO2005066202A3 (en) | Bacillus cry9 family members | |
| PL1776455T3 (pl) | Enzym lipolityczny, jego zastosowania w przemyśle spożywczym | |
| EP1569695A4 (en) | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | |
| WO2004065580A3 (en) | Mesecnhymal stem cells as a vehicle for ion channel transfer in syncytial structures | |
| WO2004011610A3 (en) | Antisense modulation of polo-like kinase expression | |
| WO2003097662A8 (en) | Antisense modulation of apolipoprotein b expression | |
| EP1250157A4 (en) | ANTISENS MODULATION OF THE EXPRESSION OF THE INDUCIBLE NITROGEN MONOXIDE SYNTHASE | |
| WO2001032832A3 (en) | Antisense inhibition of nucleolin expression | |
| WO2007093848A3 (en) | Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori | |
| WO2004016754A3 (en) | ANTISENSE MODULATION OF Nav1.3 EXPRESSION | |
| WO2005058945A3 (de) | Genvarianten die für proteine aus dem stoffwechselweg von feinchemikalien kodieren | |
| BR9905785A (pt) | Processo de fermantação para a preparação de ácido d-panto-tênico utilizando cepas da famìlia enterobacteriaceae | |
| WO2003000656A3 (en) | Antisense modulation of transforming growth factor beta receptor ii expression | |
| ATE514718T1 (de) | Peptabody für krebsbehandlung | |
| WO2007056331A3 (en) | Compositions and methods for inhibiting expression of factor v leiden mutant gene | |
| WO2002101065A3 (en) | Process for the preparation of d-pantothenic acid and/or salts thereof | |
| WO2003023044A3 (en) | Process for the production of l-amino acids using coryneform bacteria | |
| EP1813289A4 (en) | MEDICINAL COMPOSITION FOR THE TREATMENT OF CANCER OR DIABETES | |
| EP1677739A4 (en) | METHODS FOR IDENTIFYING AGENTS THAT INHIBIT THE GROWTH OF CANCER CELLS |